Drug intelligence / Profile preview

BKR-017

Development stage: Phase 2
Lead developer: BioKier
Modality: Drug Delivery Systems
Administration: Oral

Overview

BKR-017 is a colon-targeted, sustained-release butyrate tablet developed by BioKier, Inc. It's designed to deliver butyrate to the lower gut to stimulate L-cells, which helps correct deficiencies in gut hormone secretion. This mechanism aims to improve insulin sensitivity and metabolic control in both type 1 and type 2 diabetes patients.

Targets

HCAR2 (Hydroxycarboxylic acid receptor 2)HDAC (HDAC family)FFAR3 (Free fatty acid receptor 3)FFAR2

Beyond the preview

Go deeper on BKR-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BKR-017.

Explore the full profile